![\"injection](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/04\/676660337_highres.jpg\")
<\/p>\n <\/p>\n
GLP-1 drugs have dramatically changed the outlook for people with obesity. <\/p>\n
Gaetan Bally \/ Keystone <\/p>\n
After missing the first wave of GLP-1 blockbusters, Roche is investing billions in a new generation of obesity treatments. With Novo Nordisk and Eli Lilly dominating the market, can the Swiss pharma giant still find a foothold?\n<\/p>\n
Listen to the article <\/p>\n
Listening the article <\/p>\n
Toggle language selector <\/p>\n
English (US) <\/p>\n
English (British) <\/p>\n
Generated with artificial intelligence. <\/p>\n
This content was published on <\/p>\n
April 2, 2026 – 09:16\n<\/p>\n
In early March, Swiss pharma giant Roche put out some good news about the obesity drug candidate Petrelintide it\u2019s developing with Danish biotech Zealand Pharma. In a phase II trialExternal link<\/a>, the medication, injected once a week, met its primary endpoint of statistically significant weight loss. Participants shed on average 10.7% of their body weight and sustained the loss to 42 weeks with only mild side-effects.<\/p>\n But investors weren\u2019t impressed. Shares of Zealand Pharma dropped by a record 35% the day after the announcement, while Roche fell around 3%.<\/p>\n In today\u2019s world of obesity drugs, 10.7% weight loss is hardly remarkable. Users of Eli Lilly\u2019s Zepbound (tirzepatide) and Novo Nordisk\u2019s Wegovy (semaglutide) have reported losing 15-20%. In clinical trials of Zepbound, some participants shed upwards of 25% of their body weight.<\/p>\n But the future isn\u2019t only about maximising weight loss, says Manu Chakravarthy, Roche\u2019s global head of cardiovascular, renal, and metabolism product development and one of the executives leading its push into the obesity market.<\/p>\n \u201cWe\u2019re not just looking at the number on the scale. We\u2019re really looking at the overall health of the individual,\u201d Chakravarthy told Swissinfo. \u201cNot everybody will require the same thing at the same time over their journey with obesity and related comorbidities that can be 20, 40 even 60 years long.\u201d<\/p>\n + How Roche passed on a potential $14 billion-a-year weight-loss pill<\/a><\/p>\n Roche was among the first pharmaceutical companies to research drugs in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest GLP-1 boom began.<\/p>\n Having missed the first wave, it\u2019s now battling to catch the second wave. The Basel-based company is spending billions on research and deals with smaller biotechs to develop a broad portfolio of obesity drugs that it hopes will differentiate itself in an increasingly competitive field.<\/p>\n Defining obesity <\/p>\n The World Health Organization definesExternal link<\/a> obesity as a chronic disease characterised by abnormal or excessive fat accumulation that poses a significant risk to health. It is measured by calculating a person\u2019s body mass index (BMI) \u2013 body weight divided by height in metres squared. A BMI over 25 is considered overweight, and a reading of 30 or higher is classified as obese. The threshold varies for different ethnic groups. There is currently debateExternal link<\/a> about including criteria beyond BMI to diagnose obesity.<\/p>\n The latest GLP-1 weight loss drugs are generally approved for chronic weight management in adults with a BMI of 30\u00a0or higher and people with a BMI of 27\u00a0or higher who also have weight-related conditions like high blood pressure, type 2 diabetes, or high cholesterol.<\/p>\n Scientists are still trying to understand obesity<\/p>\n Based on simple mathematics, there should be plenty of room for Roche in a rapidly growing market. By 2050, almost 60% of adults over 25 are expected to be overweight or obese, up from 29% in 1990, with the biggest growth in sub-Saharan Africa, according to a study in The LancetExternal link<\/a>.<\/p>\n The rising number of obesity-related deaths and the costs of treating people with obesity has made it a top public health concern in many countries. The global costs of overweight and obesity are predicted to reach $3\u00a0trillion (CHF2.38 trillion) per year by 2030 and more than $18\u00a0trillion by 2060, accordingExternal link<\/a> to the World Obesity Federation.<\/p>\n Kai Reusser, Swissinfo <\/p>\n This translates into a huge market opportunity for drugmakers. SalesExternal link<\/a> of Eli Lilly\u2019s tirzepatide, sold as Mounjaro and Zepbound, more than doubled in 2025 to $36.5 billion, making it the world\u2019s best-selling medicine.<\/p>\n IQVIA, a global healthcare analytics and research group, estimates the global marketExternal link<\/a>\u00a0for anti-obesity drugs could grow from $66 billion in 2025 to $100-$200 billion a year by 2030. The huge range is due to significant uncertainty about how the market will evolve, said Sarah Rickwood, who heads thought leadership and the obesity initiative at IQVIA. Policies, prices, innovations, and patient preferences could dramatically change the market outlook, she said.<\/p>\n \u201cIt\u2019s only been five years since modern obesity medicine came on the market,\u201d Rickwood said. \u201cWe\u2019re only just starting to address this very large global health challenge.\u201d<\/p>\n + Swiss regulator and media clash over weight-loss drugs<\/a><\/p>\n The latest GLP-1 medicines have been gamechangers by suppressing appetite and slowing gastric emptying, leading to dramatic weight loss. But it\u2019s estimated that the penetration rate of GLP-1s so far is less than 10%External link<\/a> of the global eligible obese population, most of whom are in the United States.<\/p>\n GLP-1 drugs simply don\u2019t work for some patients, and women are more likely to see success than men. Some users suffer side-effects, ranging from vomiting and severe bloating to kidney damage, mental health issues, and vision problems. None of the offerings so far has been able to prevent muscle loss that frequently accompanies dramatic weight loss.<\/p>\n There are also growing questions about the long-term effects of GLP-1s. Some patients say weight loss plateaus over time, yet they fear regaining it if they come off the drugs. The latest drugs also appear to reduce the risk or severity of some of the roughly 200 comorbidities linked to obesity \u2013 including type 2 diabetes, hypertension and certain cancers \u2013 but not all.<\/p>\n + Can weight-loss drugs help curb rising obesity levels in Switzerland?<\/a><\/p>\n Scientists and pharma companies including Roche are searching for answers that might lead to new, more targeted drugs that give them an advantage in a highly competitive market.<\/p>\n As many people are likely to self-pay for these drugs, price and patient preference also influence uptake. The first GLP-1 drugs in pill form are being launched, which is expected to lead to a surge in use among patients who favour oral treatments over injections. Generics, launched this year in some countries, are also expected to improve access to weight-loss drugs, especially in low-income countries.<\/p>\n Weight-loss drugs in Switzerland <\/p>\n Novo Nordisk\u2019s Wegovy (semaglutide) was approved by Swissmedic in 2022 for weight management. Swissmedic approved Eli Lilly\u2019s Mounjaro (tirzepatide) for type 2 diabetes in 2022 and for weight management in 2024.<\/p>\n Since March 2024, GLP-1 drugs for weight loss have been\u00a0reimbursed by the country\u2019s basic health insurance provided strict criteria are met. Swissmedic is currently evaluating Eli Lilly\u2019s pill orfoglipron.<\/p>\n \u201cWe shouldn\u2019t see the obesity market or the people who live with obesity as a sort of monolith,\u201d said Rickwood. \u201cIt\u2019s going to be extremely complex, highly segmented by body mass index, comorbidities, overlap of comorbidities and other profile dimensions such as ethnicity and gender.\u201d<\/p>\n How Roche plans to get ahead<\/p>\n Companies are now clamouring to win the next wave. Last year Pfizer won a bidding war with Novo Nordisk for a small obesity drug developer, Metsera, in a deal valued at $10 billion. Several Chinese pharmaceutical companies are developing novel obesity drugs, with some in late-stage trials.<\/p>\n \u201cWe\u2019re just at the beginning of the obesity and weight loss era and so the key differentiators are amount of weight loss, improved cardiovascular health and liver and kidney function as well as price per dose,\u201d said Jens Neumann, a partner at PwC consulting firm in Switzerland and co-author of a\u00a0recent reportExternal link<\/a>\u00a0on how to win the next GLP-1 era. \u201cCurrently, any product that has two-digit percentage weight loss has a chance.\u201d<\/p>\n Kai Reusser, Swissinfo <\/p>\n But Roche\u2019s strategy hinges on a bet that the market will shift from an obsession with maximum weight loss to a focus on precision metabolic health, an approach where medicines are tailored to an individual\u2019s biology. Chakravarthy is convinced it has a leg up on competitors because of its legacy in obesity research, its \u201cpatient-centric approach\u201d, and its diagnostics expertise, which can help identify risk factors for obesity.<\/p>\n To increase the chances of success, it has boosted its drug pipeline through a CHF11 billion ($13.8 billion) spending spree targeting what Chakravarthy said are \u201cunique assets that can address individual patient needs\u201d.<\/p>\n Central to this is\u00a0Petrelintide. Unlike GLP-1s that target appetite and gastric slowing, Petrelintide is an amylin analogue that mimics a natural pancreatic hormone to increase satiety with potentially milder side effects. Roche is positioning it as a gentler alternative for those who cannot tolerate the nausea often associated with some GLP-1 drugs.<\/p>\n \n More<\/p>\n More <\/p>\n Roche\u2019s big bet on big diseases <\/p>\n This content was published on <\/p>\n Oct 20, 2024 <\/p>\n Swiss pharma giant Roche is the latest company to refocus its R&D investment on diseases like obesity that weigh heavily on healthcare budgets. <\/p>\n![\"\"](\"https:\/\/www.swissinfo.ch\/content\/wp-content\/uploads\/sites\/13\/2026\/04\/obesity_worldwide-eng.svg?ver=f2aff5d5\")
<\/p>\n![\"\"](\"https:\/\/www.swissinfo.ch\/content\/wp-content\/uploads\/sites\/13\/2026\/04\/drug_availability-eng_22e1ac.svg?ver=c797cd7d\")
<\/p>\n![\"injection\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/GettyImages-2148794361.jpg\")
<\/p>\n